Immediate vs delayed radiation after chemo-immunotherapy for metastatic NPC
Part of Cancer clinical trials.
This trial tests whether giving radiation therapy to the main tumor right after chemo-immunotherapy is better than waiting until the cancer comes back, in people with newly diagnosed metastatic nasopharyngeal cancer. It aims to see which approach helps you live longer and have fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with a type of nasopharyngeal cancer that has spread to other parts of the body (metastatic), and you have not had any prior treatment for it.
- You are in good physical condition, able to do your daily activities without help (ECOG 0 or 1).
- After 4-6 cycles of chemotherapy plus a PD-1 inhibitor (immunotherapy), your cancer has either disappeared or shrunk significantly (complete or partial response).
- You have no active or uncontrolled health problems like autoimmune disease, heart disease, lung disease, hepatitis B or C, or HIV, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with nasopharyngeal cancer that has come back in the same area. It tests whether giving additional radiation right after chemo plus immunotherapy works better than waiting to see if more radiation is needed later.
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
This trial tests whether a smaller radiation treatment area is as effective as the usual larger one for people whose metastatic nasopharyngeal cancer has responded well to first-line chemotherapy plus immunotherapy. It aims to reduce side effects while keeping the cancer under control.
This trial tests a new way to give radiation therapy after immunotherapy and chemotherapy for people with advanced nasopharyngeal cancer (NPC) that has partially shrunk. It aims to see if a different radiation schedule works better and has fewer side effects.
This trial tests whether a targeted radiation therapy, combined with the immunotherapy drug toripalimab before and after treatment, can reduce side effects while still effectively treating nasopharyngeal cancer. It is for patients with certain tumor sizes or stages who have not had prior neck radiation or immunotherapy.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
Hear when a new Nasopharangeal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.